Piccolo® xpress
On-The-Spot Chemistry Results in minutes
The Piccolo xpress is a compact, portable clinical chemistry system designed for on-site patient testing. Roughly the size of a shoebox, health care providers use the easy to follow color touch screen commands to perform routine multi-chemistry panels. 0.1cc of whole blood, serum or plasma is added directly to the patented 8-cm diameter single use plastic disc containing the liquid diluent and dry reagents. The disc is placed in the analyzer drawer where centrifugal and capillary forces are used to mix the reagents and sample in the disc. The Piccolo xpress monitors the reagent reactions simultaneously using nine wavelengths, calculates the results from the absorbance data and reports the results. The Piccolo xpress self-calibrates with each run and the on-board continuous intelligent Quality Control (iQCT) monitors the analyzer, reagent reactions and sample to ensure chemistry and instrument integrity. This assures you the highest quality and accuracy in results. Results are ready in approximately 12 minutes with a "hard copy" report suitable for the patient file or transferred to a computer, printer or an LIS/EMR. This enables you to rapidly obtain critical diagnostic information at point of care. The easy-to-use, low maintenance system requires no special training to operate.
16.7.09
PHILIPS GEMINI BIG BORE PET/CAT
PHILIPS GEMENI BIG BORE PET/CAT available in USA. Can take 500 lb patient. Also patient does not have to hold breath at any time.
CONFORMIS BESPOKE KNEE IMPLANTS
ConforMIS Raises $50 Million from Global Investors
Burlington, Mass. - July 13, 2009 - In its largest round of funding to date, privately-held medical-device company ConforMIS, Inc. raised $50 million from private-equity and sovereign-wealth funds in the U.S. Asia, Europe and the Middle East. ConforMIS reached this milestone in June, in a process that began in 2008.
"With this round of funding, we believe we are well positioned to continue investing in our breakthrough, patient-specific orthopedic implant technologies. Our technology platforms provide a scalable approach to the patient-specific design and manufacture of not just the instruments, but the actual implants as well," said Philipp Lang, MD, Chief Executive Officer and Chairman of the Board of ConforMIS. "With our personalized approach to both the implants and instruments, we think the potential for product and business model innovation is substantial."
Founded in 2004, ConforMIS has developed and commercialized the first and only line of personalized resurfacing implants and instruments for the routine treatment of knee osteoarthritis, a $6 billion global market. ConforMIS implans are a less-invasive, patient-specific alternative to traditional total knee replacement, which uses off-the-shelf components that may require significant removal of healthy tissue during the procedure. ConforMIS custom-designs and manufactures each implant from an individual's CT or MRI scan, providing a conforming fit that matches the patient's anatomy and may potentially result in less traumatic surgery, more natural kinematics, and quicker recovery.
On the strength of this unique approach, ConforMIS attracted capital sources from a variety of global invesetors. Primary funding sources for this round include later-stage and cross-over funds and international government funds. ConforMIS is now backed by several multi-billlion dollar international private-equity funds, with the single largest Series D investor being Aeris Capital (Zurich, Switzerland and Palo Alto, CA). Other investors in this round include equity funds from Asia, German, and the Middle East, including two sovereign-wealth funds, as well as venture funds who participated in previous rounds.
ConforMIS' proprietary technology for custom implants and instruments is supported by more than 250 patents and patent applications, including several foundational patents awarded this year. It's technology and intellectual property apply not just to knee replacement, the largest single category of orthopedics, but broadly to the over $20 billion dollar global orthopedics market.
ConforMIS recently announced that it has received CE Mark certification for its iDuo® bicompartmental knee resurfacing system. The company had previously received CE Mark for its iForma® implant and its iUni® unicompartmental knee resurfacing system. All devices have been cleared by the US Food and Drug Administration for marketing in the US. For more information on ConforMIS and its line of products, please visit http://www.conformis.com/.
See GERMAN SITE for OPERATION VIDEO.
Burlington, Mass. - July 13, 2009 - In its largest round of funding to date, privately-held medical-device company ConforMIS, Inc. raised $50 million from private-equity and sovereign-wealth funds in the U.S. Asia, Europe and the Middle East. ConforMIS reached this milestone in June, in a process that began in 2008.
"With this round of funding, we believe we are well positioned to continue investing in our breakthrough, patient-specific orthopedic implant technologies. Our technology platforms provide a scalable approach to the patient-specific design and manufacture of not just the instruments, but the actual implants as well," said Philipp Lang, MD, Chief Executive Officer and Chairman of the Board of ConforMIS. "With our personalized approach to both the implants and instruments, we think the potential for product and business model innovation is substantial."
Founded in 2004, ConforMIS has developed and commercialized the first and only line of personalized resurfacing implants and instruments for the routine treatment of knee osteoarthritis, a $6 billion global market. ConforMIS implans are a less-invasive, patient-specific alternative to traditional total knee replacement, which uses off-the-shelf components that may require significant removal of healthy tissue during the procedure. ConforMIS custom-designs and manufactures each implant from an individual's CT or MRI scan, providing a conforming fit that matches the patient's anatomy and may potentially result in less traumatic surgery, more natural kinematics, and quicker recovery.
On the strength of this unique approach, ConforMIS attracted capital sources from a variety of global invesetors. Primary funding sources for this round include later-stage and cross-over funds and international government funds. ConforMIS is now backed by several multi-billlion dollar international private-equity funds, with the single largest Series D investor being Aeris Capital (Zurich, Switzerland and Palo Alto, CA). Other investors in this round include equity funds from Asia, German, and the Middle East, including two sovereign-wealth funds, as well as venture funds who participated in previous rounds.
ConforMIS' proprietary technology for custom implants and instruments is supported by more than 250 patents and patent applications, including several foundational patents awarded this year. It's technology and intellectual property apply not just to knee replacement, the largest single category of orthopedics, but broadly to the over $20 billion dollar global orthopedics market.
ConforMIS recently announced that it has received CE Mark certification for its iDuo® bicompartmental knee resurfacing system. The company had previously received CE Mark for its iForma® implant and its iUni® unicompartmental knee resurfacing system. All devices have been cleared by the US Food and Drug Administration for marketing in the US. For more information on ConforMIS and its line of products, please visit http://www.conformis.com/.
See GERMAN SITE for OPERATION VIDEO.
Subscribe to:
Posts (Atom)